# Cyclophosphamide, Rituximab, and Either Prednisone or Methylprednisolone in Treating Patients With Lymphoproliferative Disease After Solid Organ Transplantation

> **NCT00066469** · PHASE2 · COMPLETED · sponsor: **Children's Oncology Group** · enrollment: 55 (actual)

## Conditions studied

- Lymphoproliferative Disorder

## Interventions

- **BIOLOGICAL:** rituximab
- **DRUG:** cyclophosphamide
- **DRUG:** methylprednisolone
- **DRUG:** prednisone

## Key facts

- **NCT ID:** NCT00066469
- **Lead sponsor:** Children's Oncology Group
- **Sponsor class:** NETWORK
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-04
- **Primary completion:** 2009-10-01
- **Final completion:** 2013-12-31
- **Target enrollment:** 55 (ACTUAL)
- **Last updated:** 2019-08-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00066469

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00066469, "Cyclophosphamide, Rituximab, and Either Prednisone or Methylprednisolone in Treating Patients With Lymphoproliferative Disease After Solid Organ Transplantation". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT00066469. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*